Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma

Gao, Jie; Xu, Qinfeng; Fu, Yao; He, Kuiqiang; Zhang, Chengwei; Zhang, Qing; Shi, Jiong; Zhao, Xiaozhi; Wang, Rui; Guo, Hongqian

doi:10.1007/s00259-020-04916-6

Cited by 40 publications

(39 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the largest study with histopathological confirmation to date, Gao et al retrospectively examined data of 36 patients with primary ccRCC. Preoperative 68 Ga-PSMA PET/CT imaging was shown to correlate with pT stage, ISUP grade, and adverse pathology characteristics such as necrosis, or rhabdoid or sarcomatoid dedifferentiation [ 29 ]. Günhe et al looked into the correlation of PSMA PET results and antigen expression in metastatic ccRCC.…”

Section: Psma Pet/ct In Clear Cell Renal Cell Carcinomamentioning

confidence: 99%

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Muselaers

Erdem

Bertolo

et al. 2022

JCM

View full text Add to dashboard Cite

Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.

show abstract

Section: Psma Pet/ct In Clear Cell Renal Cell Carcinomamentioning

confidence: 99%

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Muselaers

Erdem

Bertolo

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…A study [81] has proposed that PSMA PET/CT can be used as an imaging method for staging and restaging of RCC to improve the staging sensitivity, which can directly lead to the change of treatment in some cases, particularly, in the application of metastatic ccRCC. Gao et al [82] retrospectively examined the data of 36 ccRCC patients with preoperative 68 Ga-PSMA-11 PET/CT scan parameters (including maximal tumor diameter, mean CT value, and SUV max ) and surgical specimens (including WHO/ISUP grade and adverse pathology). ey found that SUV max could effectively differentiate WHO/ISUP grade (3-4 vs. 1-2) and adverse pathology (positive vs. negative) (both P < 0.001), however, with no difference in CT value, suggesting that PSMA PET/CTmolecular imaging can reflect the pathological features of ccRCC.…”

Section: Discussionmentioning

confidence: 99%

Application of 18F Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Monitoring Gastric Metastasis and Cancer Thrombi from Renal Cell Carcinoma

Xiong

Zhang

Zhou

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Renal cell carcinoma (RCC) with gastric metastasis is rare, particularly accompanied by multiple cancer thrombi. Methods. We reported a 66-year-old man with a history of a right radical nephrectomy because of RCC. The patient underwent 18F prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scanning after 6 months of targeted therapy because of gastric metastasis and cancer thrombi. We conducted a systematic review of the literature and identified 73 cases of RCC with gastric metastasis. We analyzed the clinicopathological characteristics, therapies, and outcomes of patients. Results. 18F-PSMA PET/CT showed a large mass in the gastric fundus and cancer thrombi in the right atrium, inferior vena cava, and splenic vein with intense tracer uptake. Other metastases with increased tracer uptake included multiple bones and abdominal lymph nodes. The majority of gastric metastasis of RCC were men (53/73, 72.6%), with a median age at presentation of 67 (from 48 to 87) years. Gastric metastasis of RCC was mainly metachronous, and presented with small polyps or mass appearance and often accompanied by multiple-site metastases and gastrointestinal symptoms. An overall median interval between nephrectomy and diagnosis of gastric metastasis was 6 (from 0.1 to 23) years, and an overall median survival time was 14 (from 0.25 to 72) months. The median interval time of solitary gastric metastasis was longer than gastric metastasis with multiple-site metastases (7 vs.5 years; P = 0.034 ). Patients with gastric and multiple-site metastases had higher mortality than patients with solitary metastasis (17 vs.1; P = 0.028 ). The patients with synchronous gastric metastasis had a shorter survival time than metachronous gastric metastasis (6 vs.17 months; P = 0.018 ). Conclusions. Postoperative follow-up of multiple imaging modalities to monitor recurrence and metastasis is necessary and important. PSMA PET/CT can improve the detection sensitivity of RCC, especially in metastatic clear cell renal cell carcinoma (ccRCC), and could provide a basis for disease staging, restaging, and therapeutic efficacy evaluation.

show abstract

“…For primary ccRCC, a recent study containing 36 patients with preoperative PET/CT and histopathological correlation reported that the PET/CT parameter SUVmax in the tumor can discriminate WHO/ISUP grade (3/4 from 1/2) and adverse pathology (tumor necrosis or sarcomatoid/rhabdoid features) with high sensitivity and specificity [ 15 ]. For the ccRCC metastases in our cohort, besides the bone metastasis, all SUVmax values were below 10, whereas in the mentioned publication regarding primary tumors, much higher SUVmax cutoff values of 16.4 and 18.5 were reported for differentiation of WHOS/ISUP grade and adverse pathology, respectively.…”

Section: Discussionmentioning

confidence: 99%

PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings

et al. 2021

View full text Add to dashboard Cite

PET/CT with prostate-specific membrane antigen (PSMA)-targeted tracers has been used in the diagnosis and staging of patients with clear cell renal cell carcinoma (ccRCC). For ccRCC primary tumors, PET parameters were shown to predict histologic grade and features. The aim of this study was to correlate PSMA PET/CT with histopathological findings in patients with metastatic recurrence of ccRCC. Patients with ccRCC who underwent PSMA-targeted PET/CT and subsequent histopathological evaluation of suspicious lesions were included. Specimens underwent immunohistochemical marking. Lesion diameter, volume and tracer uptake were correlated with the extent and intensity of molecular PSMA expression and with clinical findings. Twelve PET-positive lesions of nine patients were evaluated. Eleven ccRCC metastases and one prostate carcinoma were detected histopathologically. Molecular PSMA expression was detected in all lesions, which intensity and distribution did not correlate with PET parameters. PSMA-targeted PET/CT is a feasible tool for the evaluation of patients with ccRCC but cannot reliably predict histologic features of metastases. PSMA may also be expressed in malignant lesions other than ccRCC, leading to incidental detection of these tumors.

show abstract

Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma

Cited by 40 publications

References 27 publications

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature

Application of 18F Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Monitoring Gastric Metastasis and Cancer Thrombi from Renal Cell Carcinoma

PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings

Contact Info

Product

Resources

About